|
|
||||||||
1 Nutrition and Hormones Unit, International Agency for Research on Cancer, Lyon, France
2 School of Public Health, University of Sydney, Level 2, K25-Medical Foundation Building, Sydney, New South Wales, Australia
3 Center for Research in Human Nutrition Rhône-Alpes, Université Lyon 1, Lyon, France
4 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
5 Division of Population Health and Information, Alberta Cancer Board, Calgary, Alberta, Canada
6 UMR INSERM U449/INRA 1235, Lyon, France
7 Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
8 Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark
9 Inserm ERI 20, Institut Gustave Roussy, Paris-Sud University, EA4045 Villejuif, France
10 German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany
11 Department of Hygiene and Epidemiology, University of Athens Medical School, Athens, Greece
12 Hellenic Health Foundation, Athens, Greece
13 Molecular and Nutritional Epidemiology Unit, CSPO-Scientific Institute of Tuscany, Florence, Italy
14 Nutritional Epidemiology Unit, National Cancer Institute, Milan, Italy
15 Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy
16 Cancer Registry, Azienda Ospedaliera Civile M P Arezzo, Ragusa, Italy
17 CPO-Piemonte, Torino, Italy
18 Faculty of Medicine, Institute of Community Medicine, University of Tromsø, Tromsø, Norway
19 Public Health and Health Planning Directorate, Asturias, Spain
20 Department of Epidemiology and Cancer Registry, Catalan Institute of Oncology, Barcelona, Spain
21 Andalusian School of Public Health, Granada, Spain
22 Public Health Department of Gipuzkoa, Basque Government, San Sebastian, Spain
23 Epidemiology Department, Murcia Health Council, Murcia, Spain
24 Public Health Institute of Navarra, Pamplona, Spain
25 Department of Medicine, Malmö University Hospital, Lund University, Malmö, Sweden
26 Department of Medical Biosciences, Umeå University, Umeå, Sweden
27 National Institute of Public Health and the Environment, Centre for Nutrition and Health, Bilthoven, The Netherlands
28 Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
29 MRC Dunn Human Nutrition Unit, Cambridge, UK
30 Department of Public Health and Primary Care, MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, University of Cambridge, Cambridge, UK
31 Clinical Gerontology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
32 Cancer Research UK Epidemiology Unit, University of Oxford, Oxford, UK
33 Department of Epidemiology and Public Health, Imperial College London, London, UK
(Correspondence should be addressed to A E Cust; Email: annec{at}health.usyd.edu.au)
To clarify the role of metabolic factors in endometrial carcinogenesis, we conducted a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC), and examined the relation between prediagnostic plasma lipids, lipoproteins, and glucose, the metabolic syndrome (MetS; a cluster of metabolic factors) and endometrial cancer risk. Among pre- and postmenopausal women, 284 women developed endometrial cancer during follow-up. Using risk set sampling, 546 matched control subjects were selected. From conditional logistic regression models, high-density lipoprotein cholesterol (HDL-C) levels were inversely associated with risk body mass index (BMI)-adjusted relative risk (RR) for top versus bottom quartile 0.61 (95% confidence intervals (CI) 0.38–0.97), Ptrend = 0.02). Glucose levels were positively associated with risk (BMI-adjusted RR top versus bottom quartile 1.69 (95% CI 0.99–2.90), Ptrend = 0.03), which appeared stronger among postmenopausal women (BMI-adjusted RR top versus bottom tertile 2.61 (95% CI 1.46–4.66), Ptrend = 0.0006, Pheterogeneity = 0.13) and never-users of exogenous hormones (Pheterogeneity = 0.005 for oral contraceptive (OC) use and 0.05 for hormone replacement therapy-use). The associations of HDL-C and glucose with risk were no longer statistically significant after further adjustment for obesity-related hormones. Plasma total cholesterol, Low-density lipoprotein cholesterol (LDL-C), and triglycerides were not significantly related to overall risk. The presence of MetS was associated with risk (RR 2.12 (95% CI 1.51–2.97)), which increased with the number of MetS factors (Ptrend = 0.02). An increasing number of MetS factors other than waist circumference, however, was marginally significantly associated with risk only in women with waist circumference above the median (Pinteraction = 0.01). None of the associations differed significantly by fasting status. These findings suggest that metabolic abnormalities and obesity may act synergistically to increase endometrial cancer risk.
This article has been cited by other articles:
![]() |
T. Bjorge, T. Stocks, A. Lukanova, S. Tretli, R. Selmer, J. Manjer, K. Rapp, H. Ulmer, M. Almquist, H. Concin, et al. Metabolic Syndrome and Endometrial Carcinoma Am. J. Epidemiol., March 10, 2010; (2010) kwq006v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lane Obesity and gynaecological cancer Menopause Int, March 1, 2008; 14(1): 33 - 37. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |